September 15, 2025 — Leads & Copy — Oncotelic Therapeutics Inc. (OTCQB: OTLC), led by CEO Dr. Vuong Trieu, is utilizing AI, nanomedicine, and novel clinical models to advance RNA-based, immunotherapy, and targeted therapeutics for aggressive cancers and rare diseases. With over 500 patent applications and 75 issued patents, Oncotelic is developing a portfolio aimed at transforming cancer and rare disease treatment, joining innovators like IO Biotech Inc. (NASDAQ: IOBT), Sarepta Therapeutics Inc. (NASDAQ: SRPT), Autolus Therapeutics PLC (NASDAQ: AUTL) and Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT).
Dr. Trieu’s leadership and innovation are central to Oncotelic’s approach, focusing on solutions where traditional methods have been unsuccessful. The lead candidate, OT-101, a Phase 3 oligoneucleotide antisense therapy for pancreatic cancer, targets TGF-β to alter outcomes in deadly cancers.
Nanomedicine, valued at $189.5 billion in 2023 and projected to exceed $500 billion in the next decade, is a key component, with Oncotelic integrating AI-driven nanocarrier design with RNA-based and immunotherapy payloads.
Oncotelic is positioned for growth through partnerships and licensing, advancing commercialization pathways for OT-101 and other assets to deliver patient-centered therapies. The company’s strategy aligns R&D with commercial potential, emphasizing innovation and execution.
NetworkNewsWire Editorial Coverage
Dr. Vuong Trieu
Source: Oncotelic Therapeutics Inc.
